Despite compelling pre-clinical rationale harnessing bench-to-bedside research and an opportunity to re-purpose an existing approved drug, ibrutinib did not demonstrate radiological tumour shrinkage as per RECIST 1.1 in pre-treated patients with c-MYC and/or HER2 amplified advanced OG cancer. The gene discussed is MYC; the disease is neoplasm.